Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial

被引：0
|
作者：
Gluz, O. [1 ]
Nitz, U. A. [2 ]
Christgen, M. [3 ]
Kummel, S. [4 ]
Holtschmidt, J. [5 ]
Schumacher, J. [6 ]
Hartkopf, A. D. [7 ]
Luedtke-Heckenkamp, K. [8 ]
Just, M. [9 ]
von Schumann, R. [10 ]
Polata, S. [11 ]
Schinkoethe, T. [12 ]
Graeser-Mayer, M. K. [13 ]
Kates, R. E. [14 ]
Wuerstlein, R. [15 ]
Kreipe, H. [3 ]
Harbeck, N. [16 ]
机构：
[1] Evangeliches Krankenhaus Bethesda Klin, Breast Ctr, Monchengladbach, Germany
[2] West German Study Grp, Senol, Monchengladbach, Germany
[3] MHH, Pathol, Hannover, Germany
[4] Kliniken Essen Mitte Evang Huyssens Stiftung, Breast Unit, Essen, Germany
[5] St Elisabeth Clin Hohenlind, Breast Ctr, Cologne, Germany
[6] Palleos GmbH, Stat, Wiesbaden, Germany
[7] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany
[8] Niels Stensen Kliniken GmbH, Franziskus Hosp Harderberg, Oncol Dept, Georgsmarienhutte, Germany
[9] Onkol Schwerpunkt Praxis, Oncol, Greifswald, Germany
[10] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Monchengladbach, Germany
[11] Oncol Ctr Spandau, Oncol, Berlin, Germany
[12] LMU Klinikum Univ Munchen, Breast Ctr, Munich, Germany
[13] Westdeutsch Studiengrp GmbH, Senol, Monchengladbach, Germany
[14] Westdeutsch Studiengrp GmbH, Breast Ctr Dept, Monchengladbach, Germany
[15] LMU Klinikum Univ Munchen, Breast Ctr Dept, Munich, Germany
[16] LMU Univ Hosp, Dept Obstet & Gynecol, Breast Ctr, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA17
引用
收藏
页码：1210 / 1210
页数：1
相关论文
共 50 条
  • [41] Saci-IO HR plus : Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1+hormone receptor-positive (HR+) / HER2-metastatic breast cancer (MBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Stover, Daniel G.
    Gogineni, Keerthi
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Final analysis of WSG-ADAPT HER2+/HR-trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab plus pertuzumab weekly paclitaxel in HER2+/HR-early breast cancer (EBC).
    Nitz, Ulrike
    Gluz, Oleg
    Christgen, Matthias
    Grischke, Eva -Maria
    Augustin, Doris
    Kummel, Sherko
    Braun, Michael Wilhelm
    Potenberg, Jochem
    Kohls, Andreas
    Krauss, Katja
    Stefek, Andrea
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Fischer, Hans Holger
    Liedtke, Cornelia
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Phase IB-II combination neoadjuvant chemotherapy with docetaxel plus atezolizumab plus herceptin SC and pertuzumab (TAHP) for patients with HER2-positive early breast cancer and subsequent atezolizumab plus herceptin SC and pertuzumab (AHP) adjuvant therapy after surgery (Neo-PATH)
    Ahn, Hee Kyung
    Kim, Ji-Yeon
    Suh, Koung Jin
    Kim, Gun Min
    Sim, Sung Hoon
    Lee, Ki Hyeong
    Jung, Kyung Hae
    Im, Seok-Ah
    Park, Yeon Hee
    CANCER RESEARCH, 2020, 80 (04)
  • [44] EarLEE-2: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), intermediate-risk, early breast cancer (EBC)
    O'Shaughnessy, Joyce
    Alba, Emilio
    Bardia, Aditya
    Dent, Susan
    Dieras, Veronique
    Hortobagyi, Gabriel
    Im, Seock-Ah
    Montemurro, Filippo
    Untch, Michael
    Yardley, Denise A.
    Chakravartty, Arunava
    Germa, Caroline
    Miller, Michelle
    Slamon, Dennis
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Efficacy and safety of the combination of pertuzumab (P) plus trastuzumab (T) plus docetaxel (D) for HER-2 positive metastatic breast cancer (MBC) in pretreated patients (pts) with trastuzumab in the neo/ adjuvant setting: a retrospective real-life study
    Ricciardi, G.
    Ficorella, C.
    Iezzi, L.
    Marchetti, P.
    Pizzuti, L.
    Prestifilippo, A.
    Schifano, S.
    Maimone, S.
    Adamo, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [47] Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H plus BC): A Brown University oncology group (BrUOG) study
    Lopresti, Mary Lorraine
    Bian, Jessica J.
    Sakr, Bachir J.
    Strenger, Rochelle S.
    Legare, Robert D.
    Fenton, Mary Anne
    Witherby, Sabrina M.
    Dizon, Don S.
    Pandya, Sonali V.
    Stuckey, Ashley R.
    Edmondson, David A.
    Gass, Jennifer S.
    Emmick, Christine M.
    Graves, Theresa A.
    Cutitar, Marlene
    Olszewski, Adam J.
    Sikov, William M.
    CANCER RESEARCH, 2020, 80 (04)
  • [48] Patient (pt) time burden with IV vs subcutaneous (SC) administration of trastuzumab/pertuzumab (HP): A time and motion (T plus M) substudy of a single arm phase II trial of adjuvant endocrine therapy plus HP for stage I HER2+breast cancer
    Waks, Adrienne
    Graham, Noah
    Chen, Emily
    Frey, Anna Mae
    Attaya, Victoria
    Abbass, Ibrahim
    Fung, Anita
    Sussell, Jesse
    Cortazar, Patricia
    Harvey, Caroline
    Almeida, Kenneth
    Leth, Denise
    Chen, Wendy
    Leone, Jose
    Schumer, Susan
    Tayob, Nabihah
    Tolaney, Sara
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial
    Biganzoli, Laura
    Brain, Etienne
    Malorni, Luca
    Gombos, Andrea
    Hasler-Strub, Ursula
    Zamagni, Claudio
    Chakiba, Camille
    Roschitzki-Voser, Heidi
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
  • [50] An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N plus T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer
    Gavin, P. G.
    Kim, P. S.
    Lipchick, C.
    Langley, E.
    Feng, H.
    Meyer, G. R.
    Kim, S. Rim
    Michel, J. P.
    Jacobs, S. A.
    Srinivasan, A.
    Pogue-Geile, K. L.
    CANCER RESEARCH, 2017, 77
12345